{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:43:46Z","timestamp":1789101826852,"version":"build-2803163510"},"reference-count":125,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1053\/j.seminoncol.2015.09.028","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T10:25:54Z","timestamp":1443263154000},"page":"896-908","source":"Crossref","is-referenced-by-count":35,"title":["Overcoming Resistance to Targeted Therapies in Cancer"],"prefix":"10.1053","volume":"42","author":[{"given":"Keara L.","family":"Redmond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Papafili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lawler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Van Schaeybroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7015","key":"10.1053\/j.seminoncol.2015.09.028_bib1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"issue":"23","key":"10.1053\/j.seminoncol.2015.09.028_bib2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminoncol.2015.09.028_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.028_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"5350","key":"10.1053\/j.seminoncol.2015.09.028_bib7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.028_bib8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.028_bib9","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.028_bib10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nchembio840","article-title":"New approaches to molecular cancer therapeutics","volume":"2","author":"Collins","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib11","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1309\/4NTU-N6K4-F8JF-EWRX","article-title":"HER2\/neu amplification in breast cancer: stratification by tumor type and grade","volume":"117","author":"Hoff","year":"2002","journal-title":"Am J Clin Pathol"},{"issue":"16","key":"10.1053\/j.seminoncol.2015.09.028_bib12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00384-002-0427-2","article-title":"Abnormal expression of E-cadherin, beta-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis","volume":"18","author":"Ougolkov","year":"2003","journal-title":"Int J Colorectal Dis"},{"issue":"9742","key":"10.1053\/j.seminoncol.2015.09.028_bib14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"56","key":"10.1053\/j.seminoncol.2015.09.028_bib15","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1038\/sj.onc.1204082","article-title":"The EGF receptor family as targets for cancer therapy","volume":"19","author":"Mendelsohn","year":"2000","journal-title":"Oncogene"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.028_bib16","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model","volume":"1","author":"Goldstein","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.028_bib18","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","article-title":"Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials","volume":"48","author":"Bokemeyer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.028_bib19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2015.09.028_bib20","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2015.05.017","article-title":"Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials","volume":"51","author":"Peeters","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib21","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"Loupakis","year":"2009","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.028_bib23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s40265-015-0386-x","article-title":"Panitumumab in metastatic colorectal cancer: the importance of tumour RAS Status","volume":"75","author":"Peeters","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdn541","article-title":"PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients","volume":"20","author":"Perrone","year":"2009","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1053\/j.seminoncol.2015.09.028_bib25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.028_bib26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.028_bib27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.10230","article-title":"ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells","volume":"98","author":"Ciardiello","year":"2002","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1053\/j.seminoncol.2015.09.028_bib28","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.028_bib29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.028_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"issue":"7153","key":"10.1053\/j.seminoncol.2015.09.028_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"25","key":"10.1053\/j.seminoncol.2015.09.028_bib33","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminoncol.2015.09.028_bib35","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"6892","key":"10.1053\/j.seminoncol.2015.09.028_bib36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib39","first-page":"1537","article-title":"The use of bevacizumab in non-small cell lung cancer: an update","volume":"34","author":"Lauro","year":"2014","journal-title":"Anticancer Res"},{"issue":"23","key":"10.1053\/j.seminoncol.2015.09.028_bib40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib41","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.028_bib42","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA Approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.2609","article-title":"Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer","volume":"18","author":"Montagut","year":"2012","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.028_bib44","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.028_bib45","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib46","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/1078-0432.CCR-07-4367","article-title":"EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation","volume":"14","author":"Trowe","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1053\/j.seminoncol.2015.09.028_bib47","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.028_bib48","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"120","key":"10.1053\/j.seminoncol.2015.09.028_bib49","doi-asserted-by":"crossref","first-page":"120ra17","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Translat Med"},{"issue":"18","key":"10.1053\/j.seminoncol.2015.09.028_bib50","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/0008-5472.CAN-11-1340","article-title":"A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors","volume":"71","author":"Sasaki","year":"2011","journal-title":"Cancer Res"},{"issue":"24","key":"10.1053\/j.seminoncol.2015.09.028_bib51","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u02bcs tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.seminoncol.2015.09.028_bib52","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N Engl J Med"},{"issue":"52","key":"10.1053\/j.seminoncol.2015.09.028_bib53","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.028_bib54","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Disc"},{"issue":"75","key":"10.1053\/j.seminoncol.2015.09.028_bib55","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci Translat Med"},{"issue":"31","key":"10.1053\/j.seminoncol.2015.09.028_bib56","doi-asserted-by":"crossref","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib57","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-08-4055","article-title":"PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR","volume":"69","author":"Sos","year":"2009","journal-title":"Cancer Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.028_bib58","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.18632\/oncotarget.3241","article-title":"Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6\/STAT3\/Jagged-1\/Notch positive feedback loop","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"16","key":"10.1053\/j.seminoncol.2015.09.028_bib59","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.18632\/oncotarget.1955","article-title":"ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer","volume":"5","author":"Feldinger","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/sj.bjc.6602926","article-title":"PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer","volume":"94","author":"Fujita","year":"2006","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1053\/j.seminoncol.2015.09.028_bib62","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-08-4490","article-title":"Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res"},{"issue":"7326","key":"10.1053\/j.seminoncol.2015.09.028_bib63","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.028_bib64","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Disc"},{"key":"10.1053\/j.seminoncol.2015.09.028_bib66","doi-asserted-by":"crossref","first-page":"14472","DOI":"10.18632\/oncotarget.3991","article-title":"Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.028_bib67","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J Pathol"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib68","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1021\/mp200261n","article-title":"The emergence of drug transporter-mediated multidrug resistance to cancer chemotherapy","volume":"8","author":"Wu","year":"2011","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib69","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","article-title":"Heterogeneity of kinase inhibitor resistance mechanisms in GIST","volume":"216","author":"Liegl","year":"2008","journal-title":"J Pathol"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib70","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.028_bib71","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Grosso","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"10.1053\/j.seminoncol.2015.09.028_bib72","doi-asserted-by":"crossref","first-page":"8387","DOI":"10.1073\/pnas.0803383105","article-title":"Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors","volume":"105","author":"Tarn","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7404","key":"10.1053\/j.seminoncol.2015.09.028_bib73","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"7404","key":"10.1053\/j.seminoncol.2015.09.028_bib74","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"issue":"224","key":"10.1053\/j.seminoncol.2015.09.028_bib75","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Translat Med"},{"issue":"99","key":"10.1053\/j.seminoncol.2015.09.028_bib76","doi-asserted-by":"crossref","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci Translat Med"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib77","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer","volume":"3","author":"Bardelli","year":"2013","journal-title":"Cancer Disc"},{"issue":"24","key":"10.1053\/j.seminoncol.2015.09.028_bib78","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1158\/1078-0432.CCR-14-0774","article-title":"TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells","volume":"20","author":"Hobor","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib79","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat Genet"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.028_bib80","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm.3667","article-title":"Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer","volume":"20","author":"Lovly","year":"2014","journal-title":"Nat Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nm.2713","article-title":"A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer","volume":"18","author":"Ng","year":"2012","journal-title":"Nat Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib82","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nm.2725","article-title":"In cancer drug resistance, germline matters too","volume":"18","author":"Cheng","year":"2012","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib83","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.yexcr.2010.02.045","article-title":"Hallmarks of cancer: interactions with the tumor stroma","volume":"316","author":"Pietras","year":"2010","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib84","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13104-015-1197-6","article-title":"The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines","volume":"8","author":"Boeckx","year":"2015","journal-title":"BMC Res Notes"},{"issue":"7408","key":"10.1053\/j.seminoncol.2015.09.028_bib85","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib87","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1541-7786.MCR-05-0261","article-title":"Inflammation, a key event in cancer development","volume":"4","author":"Lu","year":"2006","journal-title":"Mol Cancer Res"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.028_bib88","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Disc"},{"issue":"25","key":"10.1053\/j.seminoncol.2015.09.028_bib89","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2015.09.028_bib90","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"issue":"19","key":"10.1053\/j.seminoncol.2015.09.028_bib91","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminoncol.2015.09.028_bib92","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","article-title":"al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib","volume":"23","author":"Reichardt","year":"2012","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1053\/j.seminoncol.2015.09.028_bib93","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.2011.39.9394","article-title":"Efficacy and safety of regorafenib in patients with metastatic and\/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial","volume":"30","author":"George","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9544","key":"10.1053\/j.seminoncol.2015.09.028_bib94","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.028_bib95","doi-asserted-by":"crossref","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-14-1397","article-title":"Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients","volume":"20","author":"Garner","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib96","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-14-1432","article-title":"Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer","volume":"5","author":"Dienstmann","year":"2015","journal-title":"Cancer Disc"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib97","doi-asserted-by":"crossref","first-page":"646","DOI":"10.5306\/wjco.v5.i4.646","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer","volume":"5","author":"Asami","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"18","key":"10.1053\/j.seminoncol.2015.09.028_bib98","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.028_bib99","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-13-0314","article-title":"Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC","volume":"3","author":"Walter","year":"2013","journal-title":"Cancer Disc"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib100","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJMc1506831","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"373","author":"Sequist","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2015.09.028_bib101","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-14-2789","article-title":"EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors","volume":"21","author":"Ercan","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.028_bib102","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1158\/0008-5472.CAN-14-3167","article-title":"Stetson D, Markovets AA, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models","volume":"75","author":"Eberlein","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib103","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat Med"},{"issue":"15","key":"10.1053\/j.seminoncol.2015.09.028_bib104","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib105","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Disc"},{"issue":"5","key":"10.1053\/j.seminoncol.2015.09.028_bib106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.028_bib107","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-14-3157","article-title":"FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"21","author":"Khozin","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1053\/j.seminoncol.2015.09.028_bib108","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1053\/j.seminoncol.2015.09.028_bib109","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.seminoncol.2015.09.028_bib110","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl 3","key":"10.1053\/j.seminoncol.2015.09.028_bib111","article-title":"Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): the HERACLES trial","volume":"33","author":"Siena","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2015.09.028_bib112","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-12-0440","article-title":"Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer","volume":"3","author":"Sang","year":"2013","journal-title":"Cancer Disc"},{"issue":"9","key":"10.1053\/j.seminoncol.2015.09.028_bib113","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"Janjigian","year":"2014","journal-title":"Cancer Disc"},{"issue":"20","key":"10.1053\/j.seminoncol.2015.09.028_bib114","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminoncol.2015.09.028_bib116","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1038\/ncomms7139","article-title":"Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition","volume":"6","author":"Goldman","year":"2015","journal-title":"Nat Commun"},{"issue":"6","key":"10.1053\/j.seminoncol.2015.09.028_bib117","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/CMR.0b013e3283541541","article-title":"Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor","volume":"22","author":"Seghers","year":"2012","journal-title":"Melanoma Res"},{"issue":"7494","key":"10.1053\/j.seminoncol.2015.09.028_bib118","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1053\/j.seminoncol.2015.09.028_bib119","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2015.09.028_bib120","article-title":"Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L\/3L NSCLC (POPLAR)","volume":"33","author":"Spira","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2015.09.028_bib121","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Disc"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"issue":"8","key":"10.1053\/j.seminoncol.2015.09.028_bib123","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1634\/theoncologist.2015-0014","article-title":"Consortium SC. Changing the paradigm-multistage multiarm randomized trials and stratified cancer medicine","volume":"20","author":"Lawler","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1053\/j.seminoncol.2015.09.028_bib124","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1158\/2159-8274.CD-10-0010","article-title":"The BATTLE trial: personalizing therapy for lung cancer","volume":"1","author":"Kim","year":"2011","journal-title":"Cancer Disc"},{"issue":"36","key":"10.1053\/j.seminoncol.2015.09.028_bib125","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2013.50.7905","article-title":"Evaluating many treatments and biomarkers in oncology: a new design","volume":"31","author":"Kaplan","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775415001980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T20:37:02Z","timestamp":1748637422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775415001980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0093775415001980"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2015.09.028","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}